Quand CRAF remplace BRAF dans le mélanome

Medecine/Sciences

Volumn 27, Issue 10, 2011, Pages 817-819

  Dumaz, Nicolas ^a,b,c   Bagot, Martine ^a,b,c   Bensussan, Armand ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CP-675,206; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MONOCLONAL ANTIBODY; TICILIMUMAB;

ANIMAL; DRUG ANTAGONISM; HUMAN; IMMUNOTHERAPY; MELANOMA; METASTASIS; NOTE;

ANIMALS; ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; MELANOMA;

EID: 80455172701     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20112710008     Document Type: Article

References (12)

1. Robert C, Mateus C. Anticorps anti—CTLA 4: une avancée thérapeutique majeure dans le traitement du mélanome métastatique. Med Sci 2011; 27: 850-8.
2. Delevoye C, Giordano F, van Niel G, Raposo G. La biogenèse des mélanosomes: l’échiquier de la pigmentation. Med Sci (Paris) 2011; 27: 153-62.
3. Galmiche A, Ezzoukhry Z. Régulation de la survie cellulaire par les kinases de la famille RAF. Med Sci (Paris) 2010; 26: 729-33.
4. Dalle S, Martin-Denavit T, Thomas L. Hypervariabilité génotypique des mélanomes: un défi thérapeutique. Med Sci (Paris) 2006; 22: 178-82.
5. Bertolotto C, Busca R, Ballotti R, Ortonne JP. L’AMP cyclique est un régulateur de la pigmentation de la peau. Med Sci (Paris) 2001; 17: 177-85.
6. Smalley KS, Nathanson KL, Flaherty KT. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res 2009; 69: 3241-4.
7. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
8. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011; 19: 11-5.
9. Dumaz N, Hayward R, Martin J, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006; 66: 9483-91.
10. Marquette A, Andre J, Bagot M, et al. ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Nat Struct Mol Biol 2011; 18: 584-91.
11. Cox AD, Der CJ. The raf inhibitor paradox: unexpected consequences of targeted drugs. Cancer Cell 2010; 17: 221-3.
12. Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. BrJ Pharmacol 2006; 147 (suppl 1): S252-7.